<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Other Dermatologic Condition Drugs and Topical Anti-infectives for Burns</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Other Dermatologic Condition Drugs and Topical Anti-infectives for Burns</md:title>
    <md:content-id>m00472</md:content-id>
    <md:uuid>7a11071e-cb35-4059-b1f7-eff142faed9b</md:uuid>
  </metadata>
  <content>
    <section class="learning-objectives" id="sect-00001">
    <title>Learning Outcomes</title>
    <para id="para-00001">By the end of this section, you should be able to:</para>
    <list id="list-00001">
    <item>Identify the characteristics of drugs used to treat miscellaneous dermatologic disorders and burns.</item>
    <item>Explain the indications, actions, adverse reactions, and interactions of drugs used to treat miscellaneous dermatologic disorders and burns.</item>
    <item>Describe nursing implications of drugs used to treat miscellaneous dermatologic disorders and burns.</item>
    <item>Explain the client education related to drugs used to treat miscellaneous dermatologic disorders and burns.</item>
    </list>
    </section>
    <para id="para-00002">In addition to acne and psoriasis, there are other common skin conditions for which clients may receive treatment. In this chapter they are divided into miscellaneous dermatologic conditions and burns.</para>
       <section id="sect-00003">
    <title>Miscellaneous Dermatologic Disorders</title>
    <para id="para-00003">This section focuses on the most common dermatological disorders not yet discussed, including cutaneous warts, atopic dermatitis (eczema), contact dermatitis, impetigo, and rosacea.</para>
    <section id="sect-00004">
    <title>Cutaneous Warts</title>
    <para id="para-00004"><term id="term-00001">Cutaneous warts</term> are a form of localized viral infection, resulting in the familiar raised lesions known as warts (<link target-id="fig-00001" document="m00472"/>). Current therapies in the treatment of warts include medications that chemically burn these lesions, thus eliminating them. Cantharidin is one such drug. As a <term id="term-00002">vesicant</term>, cantharidin causes local tissue necrosis on those surfaces to which it is applied. This necrosis will eventually result in the sloughing of the wart and elimination of the virus.</para>
    <figure class="scaled-down" id="fig-00001">
    <media alt="A closeup photo of an eyelid with a wart on it. The wart is a small cluster of rough looking skin."><image mime-type="image/png" src="../../media/PHA_Figure_40_04_005.jpg"/></media>
    <caption>A cutaneous wart has an irregular shape and surface. (credit: “Filiform wart on the eyelid” by Schweintechnik/Wikimedia Commons, Public Domain)</caption>
    </figure>
    </section>
    <section id="sect-00005">
    <title>Atopic Dermatitis (Eczema)</title>
    <para id="para-00005"><term id="term-00003">Atopic dermatitis</term> (<term id="term-00004">eczema</term>) is another skin condition that requires pharmacological treatment. Unlike conditions characterized solely by local irritation, atopic dermatitis is a systemic disease that has genetic predispositions, involves the immune system, and also has environmental influences. This condition has also been linked to other disorders, including asthma and hay fever (National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2022). The etiology is not clearly understood, but treatment involves using oral and topical medications to relieve the characteristic lesions of atopic dermatitis (<link target-id="fig-00002" document="m00472"/>). Hydrocortisone and pimecrolimus are often used topically to treat atopic dermatitis.</para>
    <figure class="scaled-down" id="fig-00002">
    <media alt="A closeup photo of skin with eczema shows small, scaly, enflamed patches on the skin."><image mime-type="image/png" src="../../media/PHA_Figure_40_04_006.jpg"/></media>
    <caption>Atopic dermatitis/eczema characteristically appears as red, dry patches. (credit: “This image depicts a close view of a cutaneous lesion known as nummular eczema, which also goes by the names nummular dermatitis, or discoid eczema, which presents itself as round [PHIL 16526], or oval-shaped erythematous, itchy patches” by Susan Lindsley/Centers for Disease Control and Prevention, Public Domain)</caption>
    </figure>
    </section>
    <section id="sect-00006">
    <title>Contact Dermatitis</title>
    <para id="para-00006"><term id="term-00005">Contact dermatitis</term> is an acute inflammation caused by aggravating factors that results in swollen, red, itchy lesions (<link target-id="fig-00003" document="m00472"/>). Substances that may cause contact dermatitis include, but are not limited to, soaps, cosmetics, jewelry, and poison ivy/oak. Treatment focuses on decreasing inflammation and providing comfort and decreased pain and itching. Hydrocortisone, when applied to areas of contact dermatitis, acts to decrease inflammation, relieving the red, warm, edematous symptoms. In addition to hydrocortisone or other corticosteroid ointments, calamine lotion also may be used to reduce itching and promote healing. This solution is made by combining zinc oxide and ferric oxide, which, when applied to the skin, soothes the affected area and reduces itching and burning at the site.</para>
    <figure class="scaled-down" id="fig-00003">
    <media alt="A closeup photo of an arm with contact dermatitis shows a large enflamed rash."><image mime-type="image/png" src="../../media/PHA_Figure_40_04_007.jpg"/></media>
    <caption>Contact dermatitis is acute inflammation resulting from direct contact with irritants. (credit: “This photograph depicts an individual’s arm with a blistering poison oak rash.”/Centers for Disease Control and Prevention, Public Domain)</caption>
    </figure>
    </section>
    <section id="sect-00007">
    <title>Impetigo</title>
    <para id="para-00007"><term id="term-00006">Impetigo</term> is a cutaneous bacterial infection that occurs on the upper surface of the skin (<link target-id="fig-00004" document="m00472"/>). Typically, impetigo is seen in infants and children, although it may occasionally be seen in adults. The causative organisms are most often <emphasis effect="italics">Staphylococcus aureus</emphasis> and <emphasis effect="italics">Streptococcus pyogenes</emphasis> bacteria. Treatment encompasses application of mupirocin, a topical antibacterial. Retapamulin, another topical anti-infective used in impetigo, selectively inhibits protein synthesis to stop bacterial growth. Topical treatment with these agents usually clears impetigo, but if impetigo persists and is severe, oral antibiotics may be needed.</para>
    <figure class="scaled-down" id="fig-00004">
    <media alt="A closeup photo of an arm with impetigo shows small, round pustules, as well as some that have erupted and scabbed over."><image mime-type="image/png" src="../../media/PHA_Figure_40_04_008.jpg"/></media>
    <caption>Impetigo is characterized by vesicles, pustules, or bullae that rupture, producing sores covered by honey-colored crusts. (credit: “The lesions on the volar surface of this patient’s left forearm proved to be <emphasis effect="italics">Streptococcal</emphasis> impetigo, a dermatologic condition quite often caused by <emphasis effect="italics">Staphylococcus aureus</emphasis> bacteria, as well” by Dr. Herman Miranda, Univ.of Trujello, Peru; A. Chambers/Centers for Disease Control and Prevention, Public Domain)</caption>
    </figure>
    </section>
    <section id="sect-00008">
    <title>Rosacea</title>
    <para id="para-00008"><term id="term-00007">Rosacea</term> is a skin condition that develops from an inflammatory process, causing redness, swelling, prominent small vessels, and papular lesions on the face (<link target-id="fig-00005" document="m00472"/>). Metronidazole, an antifungal, is used in the treatment of rosacea to reduce redness and inflammatory lesions. Nurses should note that when absorbed systemically, metronidazole interacts negatively with many other medicines. When alcoholic beverages are mixed with metronidazole, a life-threatening disulfiram-like reaction may occur, resulting in palpitations, diaphoresis, flushing, nausea, and tachycardia (Stokes &amp; Abdijadid, 2019). Sodium sulfacetamide, another treatment for rosacea, is antibacterial in function and is used to cleanse the skin and eliminate bacteria. Clients with sulfa allergies should not use sodium sulfacetamide.</para>
    <figure class="scaled-down" id="fig-00005">
    <media alt="A closeup photo of a face with rosacea. The nose and cheek area is a deep red color, and there are some swollen red bumps as well."><image mime-type="image/png" src="../../media/PHA_Figure_40_04_009.jpg"/></media>
    <caption>Rosacea, consisting of red bumps and broken blood vessels, occurs on the face. (credit:“Rosacea. Erythema and telangiectasia are seen over the cheeks, nasolabial area and nose. Inflammatory papules and pustules can be observed over the nose. The absence of comedos is a helpful tool to distinguish rosacea from acne.&#8221; by Sand, M., Sand, D., Thrandorf, C. et al. &#8220;Cutaneous lesions of the nose.&#8221; <emphasis effect="italics">Head Face Med</emphasis> 6, 7 [2010]. https://doi.org/10.1186/1746-160X-6-7/BioMed Central, CC BY 2.0)</caption>
    </figure>
    <para id="para-00009"><link target-id="table-00001" document="m00472"/> lists common miscellaneous dermatologic drugs and typical routes and dosing for adult and <term class="no-emphasis" id="term-00008">pediatric clients</term>.</para>
    <table class="vertically-tight" id="table-00001">
    <tgroup cols="2">
    <colspec colnum="1" colname="c1" colwidth="1*"/>
    <colspec colnum="2" colname="c2" colwidth="2*"/>
    <thead>
    <row>
    <entry valign="top" align="center"><span class="blue-text">Drug</span></entry>
    <entry valign="top" align="center"><span class="blue-text">Routes and Dosage Ranges</span></entry>
    </row>
    </thead>
    <tbody>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00009">Hydrocortisone</term><newline/>
    (<term class="no-emphasis" id="term-00010">Cortef</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults and children >2 years:</emphasis> Apply 1% cream topically to affected area 3 times daily.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00011">Methylprednisolone</term><newline/>
    (<term class="no-emphasis" id="term-00012">Medrol</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults:</emphasis> 4–48 mg/day orally, depending on the specific disease entity being treated.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00013">Calamine lotion</term><newline/>
    (<term class="no-emphasis" id="term-00014">Calananz</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults and children >2 years:</emphasis> Apply to area as needed, let dry.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00015">Retapamulin</term><newline/>
    (<term class="no-emphasis" id="term-00016">Altabax</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults:</emphasis> Apply a thin layer to the affected area (not to exceed 100 cm<sup>2</sup>) twice daily for 5 days.<newline/>
    <emphasis effect="italics">Children &#8805;9 months:</emphasis> Apply a thin layer on areas not to exceed 2% total body surface area twice daily for 5 days.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00017">Mupirocin</term><newline/>
    (<term class="no-emphasis" id="term-00018">Bactroban</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults and children >2 months:</emphasis> Apply ointment (2%) to area 2–3 times daily.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00019">Metronidazole</term><newline/>
    (<term class="no-emphasis" id="term-00020">Flagyl</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults:</emphasis> Apply gel (0.75%) topically and rub in a thin film twice daily, morning and evening.<newline/>
    <emphasis effect="italics">Children:</emphasis> Safety and effectiveness in pediatric clients have not been established.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00021">Sodium sulfacetamide</term><newline/>
    (<term class="no-emphasis" id="term-00022">Sumaxin</term>, <term class="no-emphasis" id="term-00023">Cetamide</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults:</emphasis> Wash affected areas with 10% gel twice daily (morning and evening) or as directed by your physician.<newline/>
    <emphasis effect="italics">Children:</emphasis> Safety and effectiveness in children under 12 years has not been established.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00024">Pimecrolimus</term><newline/>
    (<term class="no-emphasis" id="term-00025">Elidel</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults and children >2 years:</emphasis> Apply a thin layer of 1% cream to affected areas twice daily.</entry>
    </row>
    <row>
    <entry valign="top" align="center"><term class="no-emphasis" id="term-00026">Cantharidin</term><newline/>
    (<term class="no-emphasis" id="term-00027">Yanth</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults and children >2 years:</emphasis> Apply topically to wart surface only; repeat every 3 weeks as needed.</entry>
    </row>
    </tbody>
    </tgroup>
    <caption><emphasis effect="bold">Drug Emphasis Table: Other Dermatologic Drugs</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
    </table>
    <note class="safety-alert" id="note-00001">
    <title>Topical Steroids</title>
    <para id="para-00010">When using <term class="no-emphasis" id="term-00028">topical steroids</term>, the application sites should not be covered with an occlusive dressing. Breathable gauze dressings may be used. Topical corticosteroids are meant to exert a local effect; however, when these medications are covered with an occlusive dressing, systemic absorption may occur, leading to systemic side effects of the drug.</para>
    </note>
    <section id="sect-00009">
    <title>Adverse Effects and Contraindications</title>
    <para id="para-00011">Adverse effects associated with topical medications for skin disorders include hypersensitivities. This is especially associated with mupirocin. Localized irritation, redness, and peeling may be noted with these medications as well. When covered with occlusive dressings, clients may experience systemic absorption, resulting in the likelihood of systemic effects. For this reason, occlusive dressings are contraindicated.</para>
    <para id="para-00012">Steroid compounds are contraindicated in fungal infections. Long-term use of pimecrolimus, a calcineurin inhibitor, has been associated with the development of lymphomas. For this reason, long-term use is contraindicated.</para>
    <para id="para-00013"><link target-id="table-00002" document="m00472"/> is a drug prototype table for common dermatologic medications featuring mupirocin. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00029">pediatric dosage</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
    <table class="vertically-tight full-width" id="table-00002">
    <tgroup cols="2">
    <colspec colnum="1" colname="c1" colwidth="1*"/>
    <colspec colnum="2" colname="c2" colwidth="1*"/>
    <tbody>
    <row>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
    <term class="no-emphasis" id="term-00030">Topical antibiotic</term><newline count="2"/>
    <span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
    Bactericidal; binds RNA transcription</entry>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosing</emphasis></span><newline/>
    <emphasis effect="italics">Adults and children >2 months:</emphasis> Apply ointment (2%) to area 2–3 times daily.</entry>
    </row>
    <row>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
    Impetigo<newline count="2"/>
    <span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
    Eradication of impetigo lesions</entry>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
    Other topical medications used concurrently<newline count="2"/>
    <span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
    No significant interactions</entry>
    </row>
    <row>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Reactions</emphasis></span><newline/>
    Atopic dermatitis<newline/>
    Contact dermatitis<newline/>
    Pruritis<newline/>
    Hypersensitivities including anaphylaxis</entry>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
    Hypersensitivity<newline count="2"/>
    Caution:<newline/>
    Avoid occlusive dressings to prevent systemic<newline /> absorption</entry>
    </row>
    </tbody>
    </tgroup>
    <caption><emphasis effect="bold">Drug Prototype Table: Mupirocin</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
    </table>
    </section>
    </section>
    </section>
    <section id="sect-00010">
    <title>Topical Anti-infectives for Burns</title>
    <para id="para-00014">The greatest risk from minor <term class="no-emphasis" id="term-00031">burns</term> is infection. Because a burn removes layers of skin, an open lesion forms, breaking the skin’s integrity and allowing bacteria and other organisms to enter the client’s body. Silver sulfadiazine and mafenide acetate are two <term class="no-emphasis" id="term-00032">topical anti-infectives</term> used in the treatment and prevention of infection for localized second- and third-degree burns. As with sodium sulfacetamide, these medications are sulfa compounds that should not be administered to those with sulfa allergies. The nurse should take care to maintain a sterile environment when applying these medications to aid in preventing bacterial transfer to the client. To remain effective, burns should be completely covered with cream at all times to prevent bacterial colonization (DailyMed, <emphasis effect="italics">Sulfamylon,</emphasis> 2023).</para>
    <para id="para-00015"><link target-id="table-00003" document="m00472"/> lists common topical medications used in treating burns with typical routes and dosing for adult and <term class="no-emphasis" id="term-00033">pediatric clients</term>.</para>
    <table class="vertically-tight" id="table-00003">
    <tgroup cols="2">
    <colspec colnum="1" colname="c1" colwidth="1*"/>
    <colspec colnum="2" colname="c2" colwidth="2*"/>
    <thead>
    <row>
    <entry valign="top" align="center"><span class="blue-text">Drug</span></entry>
    <entry valign="top" align="center"><span class="blue-text">Routes and Dosage Ranges</span></entry>
    </row>
    </thead>
    <tbody>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00034">Mafenide acetate</term><newline/>
    (<term class="no-emphasis" id="term-00035">Sulfamylon</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults and children >2 months:</emphasis> Apply cream once or twice daily, to a thickness of approximately 1/16 inch.</entry>
    </row>
    <row>
    <entry valign="middle" align="center"><term class="no-emphasis" id="term-00036">Silver sulfadiazine</term><newline/>
    (<term class="no-emphasis" id="term-00037">Silvadene</term>)</entry>
    <entry valign="top" align="left"><emphasis effect="italics">Adults and children >2 months:</emphasis> Apply cream once or twice daily, to a thickness of approximately 1/16 inch.</entry>
    </row>
    </tbody>
    </tgroup>
    <caption><emphasis effect="bold">Drug Emphasis Table: Topical Anti-infectives for Burns</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
    </table>
    <section id="sect-00011">
    <title>Adverse Effects and Contraindications</title>
    <para id="para-00016">Adverse effects associated with topical medications for burns include hypersensitivities, pruritis, localized irritation, redness, and peeling. When covered with occlusive dressings, clients may experience systemic absorption, resulting in the likelihood of systemic effects. For this reason, occlusive dressings are contraindicated. Contraindications include hypersensitivities to drugs or their components.</para>
    <para id="para-00017"><link target-id="table-00004" document="m00472"/> is a drug prototype table for common burn treatments featuring silver sulfadiazine. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00038">pediatric dosage</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
    <table class="vertically-tight full-width" id="table-00004">
    <tgroup cols="2">
    <colspec colnum="1" colname="c1" colwidth="1*"/>
    <colspec colnum="2" colname="c2" colwidth="1*"/>
    <tbody>
    <row>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Class</emphasis></span><newline/>
    Topical antibiotic<newline count="2"/>
    <span class="blue-text"><emphasis effect="bold">Mechanism of Action</emphasis></span><newline/>
    Bactericidal; disrupts cell wall</entry>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Dosing</emphasis></span><newline/>
    <emphasis effect="italics">Adults and children >2 months:</emphasis> Apply cream once or twice daily, to a thickness of approximately 1&#8537; inch.</entry>
    </row>
    <row>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Indications</emphasis></span><newline/>
    Second- and third-degree burns<newline count="2"/>
    <span class="blue-text"><emphasis effect="bold">Therapeutic Effects</emphasis></span><newline/>
    Absence of infectious organisms in wound bed</entry>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Drug Interactions</emphasis></span><newline/>
    Other topical medications used concurrently<newline/>
    Cimetidine<newline count="2"/>
    <span class="blue-text"><emphasis effect="bold">Food Interactions</emphasis></span><newline/>
    No significant interactions</entry>
    </row>
    <row>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Adverse Reactions</emphasis></span><newline/>
    Hypersensitivities<newline/>
    Necrosis<newline/>
    Erythema multiforme<newline/>
    Skin discoloration<newline/>
    Burning sensation<newline/>
    Rashes<newline/>
    Interstitial nephritis<newline/>
    Leucopenia</entry>
    <entry valign="top" align="left"><span class="blue-text"><emphasis effect="bold">Contraindications</emphasis></span><newline/>
    Hypersensitivity<newline/>
    Sulfa allergy<newline/>
    Pregnant clients approaching or at term<newline/>
    Premature infants or newborn infants during the first 2 months of life</entry>
    </row>
    </tbody>
    </tgroup>
    <caption><emphasis effect="bold">Drug Prototype Table: Silver Sulfadiazine</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
    </table>
    <note class="safety-alert" id="note-00002">
    <title>Silver Sulfadiazine</title>
    <para id="para-00018">Silver sulfadiazine is widely used for burns with low risk of adverse effects. Overdose is uncommon, but systemic absorption can still occur. Care should be taken when applying the medication near mucosal or ocular areas or when it is used over a large body surface area.</para>
    <para id="para-00019">(Source: Oaks &amp; Cindass, 2023)</para>
    </note>
    </section>
    </section>
    <section id="sect-00012">
    <title>Nursing Implications</title>
    <para id="para-00020">The nurse should do the following for clients who are using drugs for the treatment of burns:</para>
    <list list-type="bulleted" id="list-00002">
    <item>Conduct vigilant assessments for baseline, response to treatment, adverse effects, infection, and systemic absorption.</item>
    <item>Monitor creatinine for decreased renal function from possible effects of systemic absorption.</item>
    <item>Observe for hypersensitivity reactions during and after administration.</item>
    <item>Apply topical medications with gloves.</item>
    <item>Maintain aseptic technique when applying medications.</item>
    <item>Emphasize the importance of compliance with instructions and follow up with clients when necessary.</item>
    <item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
    </list>
    <note class="client-teaching" id="note-00003">
    <para id="para-00021"><emphasis effect="bold">The client using a topical medication for burns should:</emphasis></para>
    <list list-type="bulleted" id="list-00003">
    <item>Take prescribed medications exactly as directed.</item>
    <item>Wash hands well before and after application.</item>
    <item>Report side effects such as skin redness, excessive dryness, or peeling to the primary provider.</item>
    <item>Report drainage, odor, temperature above 100.4°F, or other unusual symptoms to the primary provider.</item>
    <item>Cleanse skin thoroughly before applying medication.</item>
    <item>Avoid contact with eyes and mucous membranes.</item>
    </list>
    <para id="para-00022"><emphasis effect="bold">The client using a topical medication for burns <emphasis effect="italics">should not:</emphasis></emphasis></para>
    <list list-type="bulleted" id="list-00004">
    <item>Cover the medication with occlusive dressings.</item>
    </list>
    </note>
    <note class="black-box" id="note-00004">
    <para id="para-00023">Pimecrolimus cream has been associated with skin malignancies and lymphoma. Continuous long-term use should be avoided in any age group. Its use is not indicated for children less than 2 years of age.</para>
    </note>
    <note class="single-casestudy" id="note-00005">
    <para id="para-00024">Read the following clinical scenario to answer the questions that follow.</para>
    <para id="para-00025">Melissa Allen is 27 years old. Within the last year, she has gotten married, moved to a new city, and begun graduate school. Recently, she has noticed feeling a little more tired than usual and has experienced generalized joint pain.<newline count="2"/>
    <emphasis effect="bold">History</emphasis><newline/>
    Right ankle fracture<newline/>
    Seasonal sinusitis<newline count="2"/>
    <emphasis effect="bold">Current Medications</emphasis><newline/>
    Ibuprofen, 400 mg every 4 hours as needed<newline/>
    Yasmin birth control pill (drospirenone 3 mg/ethinyl estradiol 0.03 mg)</para>
    <table class="vertically-tight full-width" id="table-00005">
    <tgroup cols="3">
    <colspec colnum="1" colname="c1" colwidth="1*"/>
    <colspec colnum="2" colname="c2" colwidth="1*"/>
    <colspec colnum="3" colname="c3" colwidth="3*"/>
    <thead>
    <row>
    <entry valign="top" align="center" namest="c1" nameend="c2"><emphasis effect="bold"><span class="blue-text">Vital Signs</span></emphasis></entry>
    <entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Physical Examination</span></emphasis></entry>
    </row>
    </thead>
    <tbody>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Temperature:</emphasis></entry>
    <entry valign="top" align="left">97.4°F</entry>
    <entry valign="top" align="left" morerows="7">
    <list list-type="bulleted" id="list-00005">
    <item><emphasis effect="italics">Head, eyes, ears, nose, throat (HEENT):</emphasis> Denies any changes in vision; responds to questions appropriately without requests for repeats</item>
    <item><emphasis effect="italics">Neurological:</emphasis> Alert and oriented × 4, pleasant affect; denies numbness, tingling, dizziness, or headache</item>
    <item><emphasis effect="italics">Cardiovascular:</emphasis> Regular heart rate and rhythm; denies palpitations; S1, S2 audible; no extra sounds noted; capillary refill +3; mucous membranes pink, moist, and intact</item>
    <item><emphasis effect="italics">Respiratory:</emphasis> Lungs clear to auscultation in all fields; denies shortness of breath</item>
    <item><emphasis effect="italics">GI:</emphasis> Abdomen soft, nontender, without distention; bowel sounds active in all quadrants; denies nausea, vomiting, diarrhea, or constipation</item>
    <item><emphasis effect="italics">GU:</emphasis> Last menstrual period 16 days ago</item>
    <item><emphasis effect="italics">Integumentary:</emphasis> Nails with cracking noted; scalp with excessive silvery scaling and reddened areas noted; skin intact to limbs and trunk except for small scaling; red areas noted bilaterally on elbows; client states she has noticed more “itching and dandruff” lately</item>
    </list></entry>
    </row>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Blood pressure:</emphasis></entry>
    <entry valign="top" align="left">126/64 mm Hg</entry>
    </row>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Heart rate:</emphasis></entry>
    <entry valign="top" align="left">88 beats/min</entry>
    </row>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Respiratory rate:</emphasis></entry>
    <entry valign="top" align="left">14 breaths/min</entry>
    </row>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Oxygen saturation:</emphasis></entry>
    <entry valign="top" align="left">100% on room air</entry>
    </row>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Pain:</emphasis></entry>
    <entry valign="top" align="left">3/10</entry>
    </row>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Height:</emphasis></entry>
    <entry valign="top" align="left">5'5"</entry>
    </row>
    <row>
    <entry valign="top" align="left"><emphasis effect="italics">Weight:</emphasis></entry>
    <entry valign="top" align="left">144 lb</entry>
    </row>
    </tbody>
    </tgroup>
    </table>
    <exercise id="exer-00001"><problem id="prob-00001"><para id="para-00026"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec03_UCSQ1"/></para></problem></exercise>
    <exercise id="exer-00002"><problem id="prob-00002"><para id="para-00027"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec03_UCSQ2"/></para></problem></exercise>
    </note>
    </section>
    <section class="chapter-summary" id="sect-00013">
    <para id="para-00028">This chapter has presented the pharmacological management of selected skin conditions: acne, psoriasis, atopic dermatitis, contact dermatitis, impetigo, rosacea, and burns. A brief introduction to each condition, specific drug treatments, routes, dosages, adverse effects, nursing interventions, and client teaching have been discussed. Additionally, a special focus on disparities in the diagnosis and treatment of skin conditions and the psychological implications of skin disorders has been included.</para>
    </section>
    <section class="review-questions" id="sect-00014">
    <title>Review Questions</title>
    <exercise id="exer-00003"><problem id="prob-00003"><para id="para-00029"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec03_RQ1"/></para></problem></exercise>
    <exercise id="exer-00004"><problem id="prob-00004"><para id="para-00030"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec02_RQ2"/></para></problem></exercise>
    <exercise id="exer-00005"><problem id="prob-00005"><para id="para-00031"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec02_RQ3"/></para></problem></exercise>
    <exercise id="exer-00006"><problem id="prob-00006"><para id="para-00032"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec03_RQ4"/></para></problem></exercise>
    <exercise id="exer-00007"><problem id="prob-00007"><para id="para-00033"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec04_RQ5"/></para></problem></exercise>
    <exercise id="exer-00008"><problem id="prob-00008"><para id="para-00034"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec04_RQ6"/></para></problem></exercise>
    <exercise id="exer-00009"><problem id="prob-00009"><para id="para-00035"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec03_RQ7"/></para></problem></exercise>
    <exercise id="exer-00010"><problem id="prob-00010"><para id="para-00036"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec04_RQ8"/></para></problem></exercise>
    <exercise id="exer-00011"><problem id="prob-00011"><para id="para-00037"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec02_RQ9"/></para></problem></exercise>
    <exercise id="exer-00012"><problem id="prob-00012"><para id="para-00038"><link class="os-embed" url="#exercise/PHAR_Ch40_Sec04_RQ10"/></para></problem></exercise>
    </section>
    <section class="references" id="sect-00015">
    <para id="para-00039">DailyMed. (Updated August 7, 2023). <emphasis effect="italics">Acitretin capsule</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2150bb0f-551b-4059-a97b-187d3ab22519</para>
    <para id="para-00040">DailyMed. (Updated January 12, 2023). <emphasis effect="italics">Acne 10% – benzoyl peroxide gel.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f216b61d-ef22-61c3-e053-2a95a90ac5f9</para>
    <para id="para-00041">DailyMed. (Updated February 15, 2011).<emphasis effect="italics"> Acnecycline – tetracycline hydrochloride ointment</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a5e4a8e-20bb-4bf8-8a2e-8dfd7f2afb49</para>
    <para id="para-00042">DailyMed. (Updated October 18, 2022). <emphasis effect="italics">Adapalene gel</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aacd5ec4-e2fa-460e-aaae-a0aba5c052e5</para>
    <para id="para-00043">DailyMed. (Updated June 5, 2023). <emphasis effect="italics">Altabax – retapamulin ointment.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c91eee4-242b-4af2-a39b-7842a9d95143</para>
    <para id="para-00044">DailyMed. (Updated December 16, 2023). <emphasis effect="italics">Amzeeq – minocycline aerosol, foam.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fd99a72-047f-4fd9-93c1-712599fd3870</para>
    <para id="para-00045">DailyMed. (Updated May 30, 2022). <emphasis effect="italics">Azelaic acid gel.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66298d50-d4e2-4852-bbab-581389c488cb</para>
    <para id="para-00046">DailyMed. (Updated May 18, 2023). <emphasis effect="italics">Calananz – calamine lotion 15% lotion.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c13db8-a0f8-5713-e053-2995a90a0ae5</para>
    <para id="para-00047">DailyMed. (Updated April 17, 2020). <emphasis effect="italics">Calcipotriene ointment.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bc020e0-b5ae-4cda-aa5b-87fa0452a6bc</para>
    <para id="para-00048">DailyMed. (Updated January 24, 2023). <emphasis effect="italics">Clear days ahead oil – free salicylic acid acne treatment and moisturizer – salicylic acid cream</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7895387-100c-4cc4-9c25-0f3b9d0f5937</para>
    <para id="para-00049">DailyMed. (Updated February 27, 2023). <emphasis effect="italics">Clindamycin hydrochloride capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2367340c-d297-4a3f-8253-6d27a0ed39cb&amp;audience=professional</para>
    <para id="para-00050">DailyMed. (Updated August 17, 2023). <emphasis effect="italics">Clindamycin phosphate topical USP, 1% solution.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19363055-9ae7-4f0f-979d-93d0ee2c803f</para>
    <para id="para-00051">DailyMed. (Updated December 8, 2023). <emphasis effect="italics">Clobetasol propionate aerosol, foam.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d5ca826-d200-42d8-b9c7-d05ecabb6ab2</para>
    <para id="para-00052">DailyMed. (Updated December 20, 2023). <emphasis effect="italics">Denorex therapeutic – coal tar and menthol shampoo</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=603bb8c1-c492-d859-e053-2a91aa0aeb33</para>
    <para id="para-00053">DailyMed. (Updated December 14, 2023). <emphasis effect="italics">Doxycycline hyclate-doxyclycine hyclate  tablet, coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f234f419-42da-4a6d-82c6-92106cd77c67</para>
    <para id="para-00081">DailyMed. (Updated August 6, 2015). <emphasis effect="italics">Elta lite tar-coal tar lotion</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23f310ab-3375-48d4-8b5b-3853385b3a32</para>
    <para id="para-00054">DailyMed. (Updated December 6, 2023). <emphasis effect="italics">Enbrel – etanercept solution and kit</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a002b40c-097d-47a5-957f-7a7b1807af7f</para>
    <para id="para-00055">DailyMed. (Updated February 23, 2021).<emphasis effect="italics"> Humira – adalimumab kit and injection, solution</emphasis>. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d</para>
    <para id="para-00056">DailyMed. (Updated October 15, 2021). <emphasis effect="italics">Infliximab injection, powder, lyophilized, for solution.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b05c174f-832c-4321-b34f-2c4ad3742269</para>
    <para id="para-00057">DailyMed. (Updated November 21, 2019). <emphasis effect="italics">Methoxsalen capsule, liquid filled.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6ec8292-9189-4ebd-862a-e1725eb29eef</para>
    <para id="para-00058">DailyMed. (Updated September 13, 2021).<emphasis effect="italics"> Methylpred DP tablet methylprednisolone tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c3f3f63-8a05-7a4a-e053-2995a90ad95a</para>
    <para id="para-00059">DailyMed. (Updated February 12, 2019). <emphasis effect="italics">Metronidazole topical gel.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49b16ff1-299d-4dd0-82a7-fdb9c6e7c7a0</para>
    <para id="para-00060">DailyMed. (Updated September 12, 2018).<emphasis effect="italics"> Minocycline hydrochloride capsule</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5fc4d50-50b2-46e0-b722-4c6b2ec47d06</para>
    <para id="para-00061">DailyMed. (Updated January 17, 2018).<emphasis effect="italics"> Mupirocin ointment</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cd006-08ba-4b3e-b012-4f31c10bd001</para>
    <para id="para-00062">DailyMed. (Updated December 17, 2022). <emphasis effect="italics">1% hydrocortisone – hydrocortisone cream.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f6acc2b-7a6e-7f98-e053-2991aa0a46e7</para>
    <para id="para-00063">DailyMed. (Updated January 24, 2019). <emphasis effect="italics">Pete and pedro – coal tar solution and menthol shampoo lotion/shampoo</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db5f10a3-2b69-41eb-94e6-a6498c62184b</para>
    <para id="para-00064">DailyMed. (Updated September 30, 2020). <emphasis effect="italics">Pimecrolimus cream.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6601e43e-ce7d-446a-8568-8e7b24b86f06</para>
    <para id="para-00065">DailyMed. (Updated August 24, 2022<emphasis effect="italics">). Rayasore kit – silver sulfadiazine kit</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2b1c32-0cea-4978-bd40-e69b97fd432c</para>
    <para id="para-00066">DailyMed. (Updated January 2, 2020). <emphasis effect="italics">Sodium sulfacetamide gel.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7b051aa-a1c4-4f0e-9278-2387155857b0</para>
    <para id="para-00067">DailyMed. (Updated September 30, 2022). <emphasis effect="italics">Stelara – ustekinumab injection, solution.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c77a9664-e3bb-4023-b400-127aa53bca2b</para>
    <para id="para-00068">DailyMed. (Updated July 3, 2023). <emphasis effect="italics">Sulfamylon – mafenide acetate cream.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=008eaa23-8f19-4e39-85ff-540c1c834a9e</para>
    <para id="para-00069">DailyMed. (Updated November 29, 2023). <emphasis effect="italics">Tazarotene creme.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa5caf83-29d5-8229-b125-d7736928f132</para>
    <para id="para-00070">DailyMed. (Updated July 5, 2023).<emphasis effect="italics"> Tetracycline hydrochloride capsule</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ce3e8dc-7fbd-4f8d-a65f-092e1ef21725</para>
    <para id="para-00071">DailyMed. (Updated January 1, 2019).<emphasis effect="italics"> Tretinoin cream</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=745cc3ce-60b4-4479-a055-316817567949</para>
    <para id="para-00072">DailyMed. (Updated July 25, 2023).<emphasis effect="italics"> Ycanth – cantharidin solution</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c9bdeaa-9822-4c69-a719-ea4a8643f59c</para>
    <para id="para-00073">Frazier, W. T., Proddutur, S., &amp; Swope, K. (2023). Common dermatologic conditions in skin of color. <emphasis effect="italics">American Family Physician</emphasis>, <emphasis effect="italics">107</emphasis>(1), 26–34. https://www.aafp.org/pubs/afp/issues/2023/0100/dermatologic-conditions-skin-of-color.html</para>
    <para id="para-00074">Habeshian, K., &amp; Cohan, B. (2020). Current issues in the treatment of acne vulgaris. <emphasis effect="italics">Pediatrics, 145</emphasis>(s2), S225–S230. https://doi.org/10.1542/peds.2019-2056L</para>
    <para id="para-00075">National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2022, November). <emphasis effect="italics">Atopic dermatitis.</emphasis> https://www.niams.nih.gov/health-topics/atopic-dermatitis.</para>
    <para id="para-00076">Oaks, R., &amp; Cindass, R. (2023). <emphasis effect="italics">Silver sulfadiazine</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK556054/</para>
    <para id="para-00077">Stokes, M., &amp; Abdijadid, S. (2019). <emphasis effect="italics">Disulfiram</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK459340/</para>
    <para id="para-00078">Sutaria, A. H., Masood, S., Saleh, H. M., &amp; Schlessinger, J. (2023). <emphasis effect="italics">Acne vulgaris</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK459173/</para>
    <para id="para-00079">Yousef, H., Alhajj, M., &amp; Sharma, S. (2022). <emphasis effect="italics">Anatomy, skin (integument), epidermis</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470464/</para>
    <para id="para-00080">Zhang, X., Xu, H., Feng, L., Wang, D., &amp; Wang, A. (2021). Exploring psychosocial adaptation among people with chronic skin disease: A grounded theory study. <emphasis effect="italics">Nursing Open, 8</emphasis>(5), 2673–2685. https://doi.org/10.1002/nop2.823</para>
    </section>
       </content>
    <glossary>
    <definition id="def-00001"><term>atopic dermatitis (eczema)</term> <meaning>a long-term, systemic inflammatory response mediated by both genetic and environmental factors expressed as patchy, red, inflamed lesions</meaning></definition>
    <definition id="def-00002"><term>contact dermatitis</term> <meaning>an acute inflammatory skin reaction to an aggravating factor resulting in local redness, itching, and fluid-filled vesicles</meaning></definition>
    <definition id="def-00003"><term>cutaneous warts</term> <meaning>bumps on the skin surface that result from a viral infection</meaning></definition>
    <definition id="def-00004"><term>impetigo</term> <meaning>a cutaneous bacterial infection that develops as a honey-colored crust on the skin surface</meaning></definition>
    <definition id="def-00005"><term>rosacea</term> <meaning>a reddened facial rash characterized by broken blood vessels and small red bumps</meaning></definition>
    <definition id="def-00006"><term>vesicant</term> <meaning>any IV drug capable of causing blistering and tissue damage if leakage around the IV site occurs</meaning></definition>
    </glossary>
</document>